ATE359087T1 - Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen - Google Patents

Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen

Info

Publication number
ATE359087T1
ATE359087T1 AT03703525T AT03703525T ATE359087T1 AT E359087 T1 ATE359087 T1 AT E359087T1 AT 03703525 T AT03703525 T AT 03703525T AT 03703525 T AT03703525 T AT 03703525T AT E359087 T1 ATE359087 T1 AT E359087T1
Authority
AT
Austria
Prior art keywords
erythropoietin
treat
heart failure
prevent heart
suffering
Prior art date
Application number
AT03703525T
Other languages
English (en)
Inventor
Gilst Wiekert Hendrikus Van
Ronald Hendrik Peter Brus
Veldhuisen Dirk Jan Van
Robert Henk Henning
Boer Rudolf Allert De
Original Assignee
Crucell Holland Bv
Stichting Klinische Farmacolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Stichting Klinische Farmacolog filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE359087T1 publication Critical patent/ATE359087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT03703525T 2002-01-09 2003-01-09 Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen ATE359087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL0200010 2002-01-09

Publications (1)

Publication Number Publication Date
ATE359087T1 true ATE359087T1 (de) 2007-05-15

Family

ID=19760786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03703525T ATE359087T1 (de) 2002-01-09 2003-01-09 Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen

Country Status (8)

Country Link
US (1) US7335490B2 (de)
EP (1) EP1471930B1 (de)
CN (1) CN1612747A (de)
AT (1) ATE359087T1 (de)
AU (1) AU2003206251B2 (de)
CA (1) CA2476538C (de)
DE (1) DE60313125T2 (de)
WO (1) WO2003057242A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CA2476538C (en) 2002-01-09 2012-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
CA2588837A1 (en) * 2004-11-22 2006-05-26 University Of Utah Research Foundation Erythropoietin for treatment of multi-organ failure
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US20100261224A1 (en) 2009-04-10 2010-10-14 Felsher Dean W Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens
CN103002833B (zh) 2010-05-25 2016-05-11 耶拿阀门科技公司 人工心脏瓣及包括人工心脏瓣和支架的经导管输送的内假体
US9867694B2 (en) 2013-08-30 2018-01-16 Jenavalve Technology Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
CN107530168B (zh) 2015-05-01 2020-06-09 耶拿阀门科技股份有限公司 在心脏瓣膜替换中具有降低的起搏器比例的装置和方法
WO2017195125A1 (en) 2016-05-13 2017-11-16 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
CN110392557A (zh) 2017-01-27 2019-10-29 耶拿阀门科技股份有限公司 心脏瓣膜模拟
CN106822903B (zh) * 2017-02-13 2019-07-23 牡丹江医学院 用于治疗心衰的药物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
ZA975264B (en) * 1996-06-17 1997-12-17 Smithkline Beecham Corp Method for treating congestive heart failure.
AU2866400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
IL145895A0 (en) 1999-04-13 2002-07-25 Kenneth S Warren Lab Modulation of excitable tissue function by peripherally administered erythropoietin
DK1533380T3 (da) * 1999-04-15 2010-02-01 Crucell Holland Bv Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
AU5462501A (en) * 2000-05-02 2001-11-12 Action Pharmaceuticals Aps Use of alpha-msh and epo for preventing or treating ischemic conditions
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
CA2476538C (en) 2002-01-09 2012-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure

Also Published As

Publication number Publication date
AU2003206251A1 (en) 2003-07-24
AU2003206251B2 (en) 2008-03-13
CA2476538A1 (en) 2003-07-17
WO2003057242A1 (en) 2003-07-17
EP1471930A1 (de) 2004-11-03
CN1612747A (zh) 2005-05-04
DE60313125D1 (de) 2007-05-24
US7335490B2 (en) 2008-02-26
CA2476538C (en) 2012-07-17
EP1471930B1 (de) 2007-04-11
US20050075287A1 (en) 2005-04-07
DE60313125T2 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
ATE533484T1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
ATE304849T1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
ATE408601T1 (de) Fredericamycin-derivate
RS20050104A (en) Indole or benzimidazole derivatives for modulating ikb kinase
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
HK1096857A1 (en) Medicamentously targeted local lipolysis
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties